No.

Publication Date

Citing Article

1

2023

Xiaosong Wei, Beibei Wang, Zixin Wu, Xiaoming Yang, Yufeng Guo, Yang Yang, Zhiwei Fang, Chengzhi Yi, Liuhui Zhang, Xin Fan, Lirong Zhang, Dongkui Song. WD repeat protein 54-mediator of ErbB2-driven cell motility 1 axis promotes bladder cancer tumorigenesis and metastasis and impairs chemosensitivity, Cancer Letters. 2023; 556: 216058216058.  https://doi.org/10.1016/j.canlet.2023.216058

2

2024

Chengxiao Fu, Shan Duan, Xiaoming Zhou, Yingcai Meng, Xisha Chen. Overexpression of COL11A1 confers tamoxifen resistance in breast cancer, npj Breast Cancer. 2024; 10: 38.  https://doi.org/10.1038/s41523-024-00645-3

3

2025

Pankaj Garg, Sravani Ramisetty, Meera Nair, Prakash Kulkarni, David Horne, Ravi Salgia, Sharad S. Singhal. Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy, Biochemical Pharmacology. 2025; 236: 116850116850.  https://doi.org/10.1016/j.bcp.2025.116850

4

2025

Shehzeen Noor, Shaukat Ali, Muhammad Summer, Khushbukhat Khan. 2025;   https://doi.org/10.1007/16833_2025_496

5

2025

Dinara Ryspayeva, Attila A. Seyhan, William J. MacDonald, Connor Purcell, Tyler J. Roady, Maryam Ghandali, Nataliia Verovkina, Wafik S. El-Deiry, Martin S. Taylor, Stephanie L. Graff. Signaling pathway dysregulation in breast cancer, Oncotarget. 2025; 16: 168.  https://doi.org/10.18632/oncotarget.28701

6

2025

Ashi Mannan, Maneesh Mohan, Thakur Gurjeet Singh. Revenge unraveling the fortress: Exploring anticancer drug resistance mechanisms in BC for enhanced therapeutic strategies, Critical Reviews in Oncology/Hematology. 2025; 210: 104707104707.  https://doi.org/10.1016/j.critrevonc.2025.104707

7

2023

Nagaraj Balan Selvaraj, Akey Krishna Swaroop, Esakkimuthukumar Mariappan, Jawahar Natarajan, Prabha Thangavelu, Jubie Selvaraj. Effect of Calcitriol in Inhibiting the Cancer Cell Growth and Promoting Apoptosis in ErbB2-positive Breast Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry. 2023; 23: 2056.  https://doi.org/10.2174/1871520623666230822100006

8

2024

Tine Ottenbourgs, Els Van Nieuwenhuysen. Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer—What Can We Learn from Breast Cancer?, Cancers. 2024; 16: 1862.  https://doi.org/10.3390/cancers16101862

9

2023

Mateusz Wylaź, Anna Kaczmarska, Dawid Pajor, Matthew Hryniewicki, Dorota Gil, Joanna Dulińska-Litewka. Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer, Biomedicine & Pharmacotherapy. 2023; 168: 115676115676.  https://doi.org/10.1016/j.biopha.2023.115676

10

2024

Esteban Acosta-Ramos, Mariana Segovia-Mendoza, Jesus A. Olivares-Reyes. 2024; 7: 237.  https://doi.org/10.1007/16833_2024_281

11

2023

Lars van der Veen, Michael Schmitt, Marcel A. Deken, Michael Lahn. Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib, International Journal of Toxicology. 2023; 42: 515.  https://doi.org/10.1177/10915818231200419

12

2022

Marzia Di Donato, Pia Giovannelli, Antimo Migliaccio, Antonio Bilancio. Inhibition of Vps34 and p110δ PI3K Impairs Migration, Invasion and Three-Dimensional Spheroid Growth in Breast Cancer Cells, International Journal of Molecular Sciences. 2022; 23: 9008.  https://doi.org/10.3390/ijms23169008

13

2024

Xiaoyan Zhang, Fengyu Yang, Zhijian Huang, Xiaojun Liu, Gan Xia, Jieye Huang, Yang Yang, Junchen Li, Jin Huang, Yuxin Liu, Ti Zhou, Weiwei Qi, Guoquan Gao, Xia Yang. Macrophages Promote Subtype Conversion and Endocrine Resistance in Breast Cancer, Cancers. 2024; 16: 678.  https://doi.org/10.3390/cancers16030678